Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.70
- Piotroski Score 1.00
- Grade Buy
- Symbol (IKT)
- Company Inhibikase Therapeutics, Inc.
- Price $3.28
- Changes Percentage (20.15%)
- Change $0.55
- Day Low $2.68
- Day High $3.33
- Year High $3.82
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $6.50
- High Stock Price Target $8.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.32
- Trailing P/E Ratio -0.51
- Forward P/E Ratio -0.51
- P/E Growth -0.51
- Net Income $-19,028,883
Income Statement
Quarterly
Annual
Latest News of IKT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Meet the 'sickfluencers' of TikTok - and don't be fooled by the outrage obscuring the real scandal | Frances Ryan
Desperate individuals turn to online platforms for assistance with disability benefits, termed "sickfluencers." This highlights systemic flaws in welfare services, emphasizing the need for support due...
By The Guardian | 7 hours ago -
Metro Detroiters speak out after appeals court upholds TikTok ban in U.S.
A federal appeals court upheld the ban on TikTok, citing national security concerns. Content creators like Jon Kung express worry over losing a platform that has provided opportunities. TikTok faces a...
By CBS News | 9 hours ago -
Appeals court upholds TikTok ban, declining to block law that would force sale
A federal appeals court upheld a law that may ban TikTok in the U.S. unless its Chinese parent company sells its stake, citing national security concerns. The decision sets the stage for a potential S...
By CBS News | 12 hours ago
